AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35258782 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlegm-dampness syndrome, blood stasis syndrome, qi deficiency constitution, blood stasis constitution
Number of subjects: 2558
Study 35258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-implant assessment
Number of subjects: 877
Study 35258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implant assessment
Number of subjects: 877
Study 35258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall research engagement
Number of subjects: 877
Study 35258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative experiences
Number of subjects: 877
Study 35258841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg daily
Number of subjects: 100
Study 35258841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35258987 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide followed by low-dose ipilimumab and nivolumab
Number of subjects: 33
Study 35259270 — intervention group
Group type: COMPARATOR
Intervention: BMI <25.0
Number of subjects: 18897
Study 35259270 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25.0-29.9
Number of subjects: 18897
Study 35259270 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9
Number of subjects: 18897
Study 35259270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher leisure-time physical activity (LTPA)
Number of subjects: 18897
Study 35259270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alcohol intake
Number of subjects: 18897
Study 35259270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary BCAAs
Number of subjects: 18897
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: During lockdown (March 1 to May 11, 2020)
Number of subjects: 833
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: During lockdown
Number of subjects: 833
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting neoadjuvant chemotherapy in resectable tumours during lockdown
Number of subjects: 833
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mFOLFIRINOX preoperative chemotherapy regimen during lockdown
Number of subjects: 833
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: After lockdown
Number of subjects: 833
Study 35259629 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 833
Study 35260030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure based cognitive behavioral therapy (ECBT)
Number of subjects: 129
Study 35260178 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device (SonoCloud-1) with 1-MHz frequency, used in combination with intravenous infusion of microbubbles, administered over 3.5 months with seven ultrasound sessions (twice per month).
Number of subjects: 10
Study 35260308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild malnutrition (n=21,092)
Number of subjects: 46485
Study 35260308 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate malnutrition (n=5,286)
Number of subjects: 46485
Study 35260308 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malnutrition (n=327)
Number of subjects: 46485
Study 35260308 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional status (control group)
Number of subjects: 46485
Study 35260313 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cardiovascular prevention program
Number of subjects: 1646
Study 35260458 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) two-dose vaccine regimen, doses given 56 days apart.
Number of subjects: 1500
Study 35260458 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed second dose of VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) vaccine.
Number of subjects: 1500
Study 35260879 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-085 antibody-drug conjugate (ADC)
Number of subjects: 0
Study 35260913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg on days 1 and 15, Irinotecan 125 mg/m²
Number of subjects: 26
Study 35260913 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study 35260962 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced Hypertension (iHTN) via norepinephrine infusion in 20-mm Hg increments
Number of subjects: 325
Study 35260962 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate induction of hypertension with higher pressure targets
Number of subjects: 325
Study 35260962 — intervention group
Group type: COMPARATOR
Intervention: Incremental approach to induced hypertension
Number of subjects: 325
Study 35261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) 0-1
Number of subjects: 144
Study 35261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) 2-3
Number of subjects: 144
Study 35261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS)
Number of subjects: 144
Study 35261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) in patients with renal insufficiency
Number of subjects: 144
Study 35261130 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TIPS-Score (MOTS) in patients with refractory ascites
Number of subjects: 144
Study 35261265 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SMI
Number of subjects: 591257
Study 35261265 — intervention group
Group type: COMPARATOR
Intervention: Patients without SMI
Number of subjects: 591257
Study 35261959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed dietary intervention
Number of subjects: 100
Study 35262412 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35262504 — intervention group
Group type: EXPERIMENTAL
Intervention: Online instant messaging peer support group with trained peer counselors on top of standard care
Number of subjects: 40
Study 35262504 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 35262780 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 21
Study 35262780 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg intravenously every 2 weeks
Number of subjects: 21
Study 35262794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (DLCO) at 3, 6, and 12 months
Number of subjects: 85
Study 35262794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest CT scans at 3 and 12 months
Number of subjects: 85
Study 35262846 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 60 mg
Number of subjects: 26
Study 35263188 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Infusion Set
Number of subjects: 0
Study 35263188 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35263663 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI consumption
Number of subjects: 156
Study 35263691 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat
Number of subjects: 688
Study 35263691 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of processed meat with high-protein foods (unprocessed red meat, poultry, dairy products, fish, eggs, grains, nuts)
Number of subjects: 688
Study 35263691 — intervention group
Group type: COMPARATOR
Intervention: Total meat, unprocessed red meat, poultry, dairy products, eggs
Number of subjects: 688
Study 35263963 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg
Number of subjects: 109
Study 35263963 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 109
Study 35263963 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 100 mg
Number of subjects: 109
Study 35264105 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMuscle (PM)
Number of subjects: 148
Study 35264105 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMuscle in Practice (PiP)
Number of subjects: 148
Study 35264105 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMuscle Implementation Pilots (IP)
Number of subjects: 148
Study 35264144 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 35264144 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 35264144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study 35264144 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 0
Study 35264144 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35264150 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly SOX (oxaliplatin and S1, every 2 weeks)
Number of subjects: 42
Study 35264246 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers identified through a 92-plex proteomic panel analysis.
Number of subjects: 406
Study 35264340 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening effort measured through the sentence-final word identification and recall (SWIR) test with single talker non-intelligible speech background noise and pupil dilation monitoring.
Number of subjects: 30
Study 35264340 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests for cognitive function evaluation.
Number of subjects: 30
Study 35264341 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 2000
Study 35264341 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 2000
Study 35264341 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatments for AEDH (including craniotomy and DC)
Number of subjects: 2000
Study 35264353 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Life Centre programmes including physical activity offers and dietary courses
Number of subjects: 189
Study 35264353 — intervention group
Group type: COMPARATOR
Intervention: Dropouts
Number of subjects: 189
Study 35264400 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMCs) from patients who had a stroke
Number of subjects: 10
Study 35264400 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMCs) from controls
Number of subjects: 10
Study 35264424 — intervention group
Group type: EXPERIMENTAL
Intervention: sNfL levels at preataxic stage (median 15.5 pg/mL [interquartile range 10.5-21.1 pg/mL])
Number of subjects: 40
Study 35264424 — intervention group
Group type: EXPERIMENTAL
Intervention: sNfL levels at ataxic stage (31.6 pg/mL [26.2-37.7 pg/mL])
Number of subjects: 40
Study 35264424 — intervention group
Group type: COMPARATOR
Intervention: sNfL levels in controls (6.0 pg/mL [4.7-8.6 pg/mL])
Number of subjects: 40
Study 35264434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 4 mg/kg plus pembrolizumab 2 mg/kg every 2 weeks
Number of subjects: 33
Study 35264559 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoPET imaging using a radiolabeled HIV Env-specific broadly neutralizing antibody
Number of subjects: 0
Study 35265135 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK retentive elements
Number of subjects: 22
Study 35265135 — intervention group
Group type: COMPARATOR
Intervention: Conventional nylon clip and metal housings
Number of subjects: 22
Study 35265225 — intervention group
Group type: EXPERIMENTAL
Intervention: One-staged hybrid operation (embolization combined with microsurgical resection)
Number of subjects: 130
Study 35265911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit devices for step count assessments; KardiaMobile for cardiac rhythm assessments; PROMs for pain and palpitations over 5 weeks.
Number of subjects: 59
Study 35265911 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal digital device and PROM data
Number of subjects: 59
Study 35266046 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (240 mg caffeine)
Number of subjects: 16
Study 35266046 — intervention group
Group type: COMPARATOR
Intervention: Coffee (240 mg caffeine)
Number of subjects: 16
Study 35266059 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 56
Study 35266059 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 56
Study 35266059 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 56
Study 35266065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum Magnetic Resonance Therapy (QMRT)
Number of subjects: 5
Study 35266132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 48
Study 35266132 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-CRP
Number of subjects: 48
Study 35266132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CRP
Number of subjects: 48
Study 35266132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PCT
Number of subjects: 48
Study 35266132 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF/blood glucose
Number of subjects: 48
Study 35266172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm laser device with a robotic arm
Number of subjects: 0
Study 35266624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR-12) with direct-acting antiviral agents (DAAs)
Number of subjects: 385
Study 35266655 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical recombinant nerve growth factor (cenegermin)
Number of subjects: 0
Study 35266655 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 35266773 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple HOPES intervention
Number of subjects: 17
Study 35266925 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 69
Study 35266925 — intervention group
Group type: COMPARATOR
Intervention: Pretransplant period factors (dialysis vintage, sclerostin, low bone volume at baseline)
Number of subjects: 69
Study 35266926 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO models
Number of subjects: 409
Study 35266926 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence models
Number of subjects: 409
Study 35266926 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of LASSO models
Number of subjects: 409
Study 35266926 — intervention group
Group type: COMPARATOR
Intervention: Previously published models
Number of subjects: 409
Study 35267093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D shear wave elastography (2D-SWE)
Number of subjects: 72
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Reordered life priorities toward private life
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III BC diagnosis
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving one's job as not very interesting
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Being an employee/clerk (vs. executive occupation)
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving no support from the supervisor at baseline
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving negative interferences of cancer in daily life
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving a positive impact from experiencing cancer
Number of subjects: 1097
Study 35267143 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1097
Study 35267254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (single-session racemic ketamine treatments, administered intravenously)
Number of subjects: 9
Study 35267254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ketamine and psychotherapy
Number of subjects: 9
Study 35267254 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine, S-ketamine, or R-ketamine
Number of subjects: 9
Study 35267535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask learning of pre-/mid-treatment FDG-PET radiomics
Number of subjects: 45
Study 35267535 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical imaging
Number of subjects: 45
Study 35267535 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET delta radiomics
Number of subjects: 45
Study 35267535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask learning FDG-PET radiomics
Number of subjects: 45
Study 35267535 — intervention group
Group type: COMPARATOR
Intervention: Clinical imaging
Number of subjects: 45
Study 35267535 — intervention group
Group type: COMPARATOR
Intervention: Delta radiomics
Number of subjects: 45
Study 35267579 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.56 MHz modulated electro-hyperthermia (mEHT) boost during neoadjuvant treatment, twice a week during radiotherapy
Number of subjects: 60
Study 35267579 — intervention group
Group type: COMPARATOR
Intervention: Whole pelvis radiotherapy of 40 Gy
Number of subjects: 60
Study 35267593 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (from the PRIMA trial)
Number of subjects: 12
Study 35267593 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (from the PAOLA-1 trial)
Number of subjects: 12
Study 35268280 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS)
Number of subjects: 40
Study 35268280 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 40
Study 35268280 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection with adjuvant erythritol air-polishing (FMDAP)
Number of subjects: 40
Study 35268280 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant-wise debridement, scaling and root planing (Q-SRP)
Number of subjects: 40
Study 35268456 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD-first group
Number of subjects: 200
Study 35268478 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg) administered 24 hours before surgery and on days 2, 3, 4, and 5 postoperatively.
Number of subjects: 101
Study 35268478 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on the same schedule as colchicine.
Number of subjects: 101
Study 35270262 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVQuest-CC Questionnaire
Number of subjects: 0
Study 35270339 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention concerning palliative care
Number of subjects: 37
Study 35271541 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS)
Number of subjects: 12006
Study 35271541 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary resuscitation (CCPR)
Number of subjects: 12006
Study 35271729 — intervention group
Group type: EXPERIMENTAL
Intervention: ß-d-N4-hydroxycytidine (NHC)
Number of subjects: 12
Study 35272132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m² administered intravenously)
Number of subjects: 25
Study 35272392 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based clinical intervention
Number of subjects: 0
Study 35272475 — intervention group
Group type: EXPERIMENTAL
Intervention: SENTINEL Device
Number of subjects: 0
Study 35272475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35272481 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsy detection of phosphorylated α-synuclein
Number of subjects: 0
Study 35272506 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35272723 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy behaviour cluster (high physical activity and low consumption of sugary products)
Number of subjects: 1391
Study 35272723 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy behaviour cluster (high consumption of fruit and vegetables)
Number of subjects: 1391
Study 35272723 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy behaviour cluster (high sedentary behaviour and low consumption of fruit and vegetables)
Number of subjects: 1391
Study 35272723 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy behaviour cluster (smoking and alcohol consumption)
Number of subjects: 1391
Study 35272771 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve replacement with the EVOQUE system
Number of subjects: 56
Study 35272799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active restoration of sinus rhythm (SR) through cardioversion and/or ablation
Number of subjects: 117
Study 35272799 — intervention group
Group type: COMPARATOR
Intervention: Absence/failure of restoration of sinus rhythm
Number of subjects: 117
Study 35272799 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous restoration of sinus rhythm
Number of subjects: 117
Study 35272808 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score (Score 1: acute MI size ≥19% LV, LVEF ≤47%, MVO >1.4% LV; Score 2: acute MI size ≥19% LV, LVEF ≤47%, IMH; Score 3: LVEF ≤45%, IMH)
Number of subjects: 604
Study 35272808 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score (Score 3: LVEF ≤45%, IMH)
Number of subjects: 604
Study 35272808 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast CMR risk score
Number of subjects: 604
Study 35272845 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment before surgery (defined as at least 1 positive test in physical, mental, and social domains).
Number of subjects: 555
Study 35272845 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty presence (29% in patients with adverse functional outcome).
Number of subjects: 555
Study 35272845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility, nutrition, medication use, physical functioning, and self-rated health before surgery.
Number of subjects: 555
Study 35272846 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNA detection in follicular fluid, cumulus cells, and endometrial samples
Number of subjects: 16
Study 35272846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertilization rate, embryo developmental potential, and clinical outcome after frozen embryo transfer
Number of subjects: 16
Study 35272946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer drug repurposing for PIK3CA-driven overgrowth
Number of subjects: 0
Study 35273012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) initiated after <3 months to 8.3 years of developing pre-diabetes
Number of subjects: 223